THOUSAND OAKS, Calif. and FREMONT, Calif., Nov. 3 /PRNewswire-FirstCall/ -
-Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) will host a joint
conference call on November 3 at 8:00 a.m. Pacific Time to discuss the
top-line results of a recently completed pivotal study of panitumumab. A
separate press release announcing these results is being issued this morning.
Live audio of the conference call will be simultaneously broadcast over
the Internet and will be available to members of the news media, investors and
the general public.
To participate in the conference call, please dial 877-817-2450 or
706-634-7548 fifteen minutes before start time. The pass code for the live
call is 2201994. A telephonic replay of the call will be available by dialing
800-642-1687 or 706-645-9291. The replay participant code is 2201994.
The webcast of the conference can be found on Amgen's Web site,
http://www.amgen.com, under Investors, and on Abgenix's Web site, http://www.abgenix.com.
The webcast will be archived and available for replay at least 72 hours after
the event.
About Amgen
Amgen discovers, develops and delivers innovative human therapeutics. A
biotechnology pioneer since 1980, Amgen was one of the first companies to
realize the new science's promise by bringing safe and effective medicines
from lab, to manufacturing plant, to patient. Amgen therapeutics have changed
the practice of medicine, helping millions of people around the world in the
fight against cancer, kidney disease, rheumatoid arthritis, and other serious
illnesses. With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve people's lives.
To learn more about our pioneering science and our vital medicines, visit
http://www.amgen.com.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of fully human therapeutic antibodies. The
company's antibody development platform includes a leading technology and
state-of-the-art manufacturing capabilities that enable the rapid generation,
selection and production of high affinity, fully human antibody product
candidates to a variety of disease targets. Abgenix leverages its leadership
position in human antibody technology to build a diversified product portfolio
through its own development efforts and the establishment of collaborations
with multiple pharmaceutical and biotechnology companies. For more information
on Abgenix, visit the company's website at http://www.abgenix.com.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
media, Trish Hawkins, +1-805-447-4587, or
investors, Arvind Sood, +1-805-447-1060, both of Amgen; or Greg
Mann of Abgenix, +1-510-284-6566
|
